Wiendl et al. [17] (ASCLEPIOS I/II, APLIOS, APOLITOS, and ALITHIOS trials) also reported on the association between IgG levels and infection risk and between IgM levels and infection risk for individuals undergoing long-term treatment with ofatumumab, concluding that no apparent association was observed between low IgG or IgM levels and risk of serious infections after 3.5 years of ofatumumab treatment. This evidence concerns the gene CD40LG and infection.